Navigation Links
Dermal in Biological Technology

Dr. Daniel Ronel Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler

... patients who are looking for a longer lasting dermal filler. Dr. Ronel has been an avid Artefill user ... is injected with Artefill similar to other dermal fillers with the key difference being its lasting ... feeling results. This is different from temporary dermal fillers that are made of different kinds of ...

Photos: FDA Approves 12-Month Labeling Update for EVOLENCE(R) Collagen-Based Facial Filler

... 12 months for EVOLENCE(R), a collagen-based dermal filler for the correction of moderate to deep ... EVOLENCE(R) is the first and only collagen dermal filler recognized to provide results through 12 ... initial treatment*. EVOLENCE(R), the first dermal filler entry for Ortho Dermatologics, was ...

BioForm Reports Financial Results for the Fourth Quarter and Full Fiscal Year Ended June 30, 2008

... update on its product pipeline: -- RADIESSE(R) dermal Filler Next-Generation Products: The Company has ... indications of its patent protected RADIESSE dermal filler technology. The first new commercial ... efforts is expected to be a form of RADIESSE dermal filler with Lidocaine which may improve ...

Radiesse(R) Dermal Filler Featured Prominently in Journal of Dermatologic Surgery Special Issue on Fillers

... recent papers demonstrate safety with Radiesse(R) dermal filler in 1000 patients over 4 years, evidence ... in various prestigious journals, Radiesse dermal filler is one of the most rigorously studied ... the safety and effectiveness of Radiesse dermal filler in treatment of nasolabial folds, ...

DermAvance Pharmaceuticals Announces Investment by Ben Franklin Technology Partners of Southeastern Pennsylvania

... a patent protected combination, second generation dermal filler. dermal fillers are used to reverse changes associated ... with the baby boomers coming of age, and the US dermal filler market is projected to reach $1 billion by ...

NeurogesX' Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union

... products for pain. Qutenza is a high-concentration capsaicin dermal patch designed to provide rapid, localized and sustained relief from ... late stage product portfolio is led by its product candidate Qutenza, a dermal patch designed to manage pain associated with peripheral neuropathic pain ...

Palomar and Q-MED AB Terminate International Distribution Agreement

... Q-MED's efforts are being concentrated on their own product line of dermal fillers. Both Palomar and Q-MED agreed that Palomar will be better served ... present challenging market conditions, Q-Med is focusing on its leading dermal filler product line, Restylane(R) as well as on the on-going launch of ...

Video: Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse(TM) -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes

... (PG) receptors. PG receptors are present in hair, particularly in the dermal papilla and outer root sheath. Although the precise mechanism of action ... portfolio, including BOTOX(R) Cosmetic; hyaluronic acid and collagen-based dermal fillers; and physician-dispensed skin care products. Allergan Medical ...

NeurogesX to Report Third Quarter 2008 Financial Results

... late stage product portfolio is led by its product candidate NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain ... a liquid, NGX-1998 is expected to be suitable for areas of the skin where dermal patches may be difficult or impractical to apply, such as the hairline. ...

NeurogesX Reports Second Quarter 2008 Results

... late stage product portfolio is led by its product candidate NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain ... a liquid, NGX-1998 is expected to be suitable for areas of the skin where dermal patches may be difficult or impractical to apply, such as the hairline. ...

NeurogesX Reports First Quarter 2008 Results

... development expected in second quarter of 2008 - NDA submission for dermal patch, NGX-4010, in PHN expected in second half ... late stage product portfolio is led by its product candidate NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain ...

Palomar and Q-MED AB Enter Into International Distribution Agreement

... the producer of Restylane, one of the most popular and widely distributed dermal fillers in the world, with over 9 million treatments provided so far. ... effects of Palomar's light-based systems with Q- MED's leading range of dermal fillers and injectable implants. Both companies are focused on developing ...

Transport Pharmaceuticals Receives Coveted Frost & Sullivan Technology Innovation Award

... of creating a system which is poised to revolutionize the field of dermal drug delivery." The Challenges and Promise of Transdermal Delivery The ... a high dose of potent drug rapidly and painlessly reaches the affected dermal tissue, while the patient avoids the potential toxicity and adverse ...

Echo Therapeutics Reports Third Quarter 2007 Results

... of well-established, FDA-approved products using Echo's AzoneTS dermal penetration enhancement technology in concert with a 505(b)(2) ... well-established, FDA-approved products using its proprietary AzoneTS(TM) dermal penetration technology. Echo has submitted a New Drug Application (NDA) to ...

NeurogesX Reports Second Quarter 2009 Results

... (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza(TM), a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions. Qutenza is currently approved in the European Union for the ...

NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application

... (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza(TM), a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions. Qutenza is currently approved in the European Union for the ...

NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results

... (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza((TM)), a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions. Qutenza is currently approved in the European Union for the ...

Seasoned Dermatologist Nissan Pilest of Irvine, CA, Joins SDS Clinical Trials as Clinical Investigator for Dermatology Division

... in the advanced injection techniques of Allergan products Juvederm and Botox, is on the Medical Education Faculty for Bioform's Radiesse long term dermal filler and also is a physician trainer for Restylane and Perlane and the new neurotoxin Dysport. He is the medical director of Total Dermatology, ...

High-Tech 'Smart' Face Mask Helps Hong Kong Families Combat Swine Flu

... terms of all the major routes of exposure, oral, dermal and inhalation, it showed no harmful effects on humans. The BioMask(TM) has been tested for dermal biocompatibility following internationally recognized standards set out in ISO10933: Biological Evaluation of Medical Devices. Tests were conducted ...

NeurogesX Added to Russell 3000 Index

... polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions. Qutenza is currently approved in the European Union for the ...

Australia: Face Mask That Kills Swine Flu Readied for Australian Pandemic Fight

... tested in terms of all the major routes of exposure, dermal and inhalation, it showed no harmful effects on humans. The BioMask has been tested for dermal biocompatibility following internationally recognized standards set out in ISO10933: Biological Evaluation of Medical Devices. Tests were conducted ...

NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)

... polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions. Qutenza is currently approved in the European Union for the ...

Orange County Laser Surgeon Nissan Pilest Tapped as Keynote Speaker at Fraxel & Thermage User Forum Held at Beckman Laser Institute

... Total Dermatology, is located in Irvine, Ca. His clinic is a popular choice for all cosmetic dermatology applications, with a special focus on dermal fillers, Botox and lasers. Consultations are available by calling (949) 727 3800 or contacting the practice via their website ...

NeurogesX to Present at Needham Life Sciences Conference

... (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza(TM), a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions. Qutenza is currently approved in the European Union for the ...

NeurogesX Receives European Commission Approval for Qutenza(TM)

... polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions. Qutenza is currently approved in the European Union for the ...

NeurogesX Reports First Quarter 2009 Results

... polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late-stage product portfolio is led by its product candidate QutenzaTM, a dermal high-concentration capsaicin patch designed to manage pain associated with peripheral neuropathic pain conditions. NeurogesX submitted a new drug ...

NeurogesX to Hold Conference Call to Discuss First Quarter 2009 Financial Results

... polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions. NeurogesX submitted a new drug application (NDA) for Qutenza to ...

NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting

... peripheral neuropathic pain, including PHN, HIV-DSP and PDN. NeurogesX' late stage product portfolio is led by its product candidate Qutenza, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that the Company believes offers significant advantages over ...

Histogen Aesthetics Launches ReGenica Rejuvenation System

... Rejuvenation System for anti-aging and post-resurfacing. Histogen Aesthetics utilizes a proprietary manufacturing process in which newborn dermal fibroblast cells are grown on beads in controlled bioreactors that maintain an embryonic-like environment, including low oxygen and low gravity ...

NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update

... polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that the Company believes offers significant advantages over ...

NeurogesX to Present at 11th Annual BIO CEO & Investor Conference

... polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late-stage product portfolio is led by its product candidate QutenzaTM, a dermal high concentration capsaicin patch designed to manage pain associated with peripheral neuropathic pain conditions, that the Company believes offers ...

Irvine Dermatologist Begins In-office Clinical Studies -- Nissan Pilest, MD Combines Multi-Use Botox in Laser Resurfacing Clinical Studies

... medical use in migraine, back pain and TML Used along with fillers, Dr. Pilest finds that Botox also tends to typically prolong the effects of the dermal fillers by restricting muscle activity that drives filler component breakdown. Dr. Pilest enthuses, "For a fast, simple and practically ...

Dr. Gail Naughton Speaks on Histogen's Business Plan and the Rise of Bioaesthetic Medicine during Commercial Translation of Regenerative Medicine

... human extracellular matrix which is grown in a simulated embryonic environment, is currently being evaluated for a variety of applications, from dermal fillers to implant coatings," said Dr. Robert Kellar, VP of Research and Development at Histogen. "Intriguing preliminary results from ...

Transdermal Diclofenac enters Phase 1 Clinical Trial in Humans

... Australia, the Principal Investigator is Professor Allan Evans. The trial is an open label, single centre bioavailability and penetration trial of dermal and systemic pharmacokinetics in 12 healthy adult volunteers, incorporating secondary endpoints of safety and tolerability. The Company expects to ...

NeurogesX to Present at Rodman & Renshaw 10th Annual Healthcare Conference

... polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that the Company believes offers significant advantages over ...

NeurogesX Reports Third Quarter 2008 Results

... polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that the Company believes offers significant advantages over ...

NeurogesX Submits NDA for NGX-4010 Dermal Capsaicin Patch for Treatment of Postherpetic Neuralgia (PHN)

... polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that the Company believes offers significant advantages over ...

Histogen Aesthetics is Created to Address Growing Medical Aesthetics Market

... San Diego/Phoenix (PRWEB) October 20, 2008 -- Histogen, Inc., a regenerative medicine company developing solutions based on the products of newborn dermal fibroblasts, today announced the creation of Histogen Aesthetics LLC, a venture developing products for the growing medical aesthetic industries ...

NeurogesX Responds to EMEA's Day 120 Questions

... polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that the Company believes offers significant advantages over ...

MIGENIX Reports First Quarter Fiscal 2009 Financial Results

... a NDA in 2011, Cutanea expects: - in the first quarter of calendar 2009, to initiate chronic toxicology studies, specifically the required dermal carcinogenicity study, which Cutanea expects will be the rate limiting activity for submission of the NDA; and - in the second half of ...
Other Contents
(Date:7/11/2014)... University of Chicago is creating a new professorship ... the University,s Institute for Molecular Engineering and the ... donation from the Millicent and Eugene Bell Foundation., ... reside within the Institute for Molecular Engineering. That ... project at the MBL,s Eugene Bell Center for ...
(Date:7/11/2014)... "mouse TRAP" to capture the early signs of kidney ... the Journal of Clinical Investigation . Their new ... extract cellular and genetic information from a variety of ... Institute for Medical Research in 2008, TRAP involves attaching ... of the cell type of interest. Scientists can then ...
(Date:7/11/2014)... 10, 2014---A team of researchers from The Chinese University ... a gene of wild soybean linked to salt tolerance, ... in saline soil. This study published online in ... novel genomic information for crop improvement. , Soybean is ... and human selection, cultivated soybeans have less genetic diversities ...
Breaking Biology News(10 mins):New professorship in tissue engineering links molecular engineering, marine biology 2BGI reports a novel gene for salt tolerance found in wild soybean 2
(Date:7/13/2014)... type-1 diabetes could improve patient care worldwide and ... the device,s inventors at the Stanford University School ... be published online July 13 in Nature ... type-1 diabetes outside hospital settings. The handheld microchips ... mellitus, which are both characterized by high blood-sugar ...
(Date:7/13/2014)... American water storage systems market is estimated to grow from ... a CAGR of 21.0%, from 2013 to 2018. The water ... North America. The U.S. is experiencing high growth on account ... collection, and the increased spending on modernization and upgradation of ... in Canada, and is rising at a rapid pace in ...
(Date:7/13/2014)... 13, 2014 Fuel additives are chemicals, ... diesel, jet fuel, kerosene, and so on, in order ... for reducing the corrosion effects caused by fuels and ... to any fuel, provide economies of scale in the ... the overall cost of the fuel products. , The ...
(Date:7/13/2014)... HealthDay Reporter FRIDAY, July 11, ... for people with diabetes is being developed to measure sugar ... report. Scientists at Brown University in Providence, R.I., created ... uses light, metal and a special enzyme that changes color ... have to prick their fingers to draw blood to check ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Recently, ... retailer, has unveiled its new range of gorgeous ... current market, the demand for elegant Quinceanera outfits ... more beautiful items. All the company’s newly released ... trends. They are all elegant and vivid. ...
Breaking Medicine News(10 mins):Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 2Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 3Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 4Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 2Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 2Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 4Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 2Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 3Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2
Other TagsOther Tags